• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

进展性多发性硬化症的临床量表:预测长期残疾。

Clinical scales in progressive MS: predicting long-term disability.

机构信息

VU University Medical Center, Amsterdam, The Netherlands.

出版信息

Mult Scler. 2012 Mar;18(3):345-50. doi: 10.1177/1352458511419880. Epub 2011 Aug 25.

DOI:10.1177/1352458511419880
PMID:21868487
Abstract

BACKGROUND

To determine which short-term changes on clinical scales including the Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW), 9-Hole Peg test (9HPT) and Guy's Neurological Disability Scale (GNDS) are most predictive of long-term outcome of disability as rated by the EDSS in progressive multiple sclerosis (MS).

METHODS

From a longitudinal database, all progressive patients, both primary (PP) and secondary (SP), were selected on the basis of at least two complete examinations being available within a time interval of 1-2 years (short-term change). All patients who fulfilled the selection criteria were invited for a third visit after an interval of at least 3 years (long-term outcome). We used ordinal logistic regression to see which early changes were most predictive of the long-term EDSS.

RESULTS

181 patients fulfilled the selection criteria. Early change on EDSS and T25FW were the best predictors of long-term EDSS; both were significant predictors in a 'single predictor' model. Early EDSS change was a slightly stronger single predictor (R(2) 0.38, Wald χ(2) 42.65, p < 0.001) compared with early T25FW change (R(2) 0.27, Wald χ(2) 12.35, p < 0.001). Adding early T25FW change to early EDSS change in a 'combined predictor' model improved prediction (p = 0.036).

CONCLUSION

Both early change on EDSS and T25FW predict long-term EDSS with comparable strength. Early change on T25FW adds significant independent information and improves the prediction model with early EDSS change only. Therefore we support the use of early T25FW examinations in future clinical trials in progressive MS.

摘要

背景

为了确定扩展残疾状况量表(EDSS)、定时 25 英尺步行(T25FW)、9 孔钉测试(9HPT)和盖氏神经功能缺损量表(GNDS)等临床量表的短期变化中哪些最能预测进展性多发性硬化症(MS)患者的长期残疾结局(EDSS 评分)。

方法

我们从纵向数据库中选择了所有符合条件的进展性患者,包括原发性进展型(PP)和继发性进展型(SP),其标准为在 1-2 年内至少有两次完整的检查(短期变化)。所有符合入选标准的患者均在至少 3 年后进行了第三次随访(长期结局)。我们使用有序逻辑回归来观察哪些早期变化最能预测长期 EDSS。

结果

共有 181 例患者符合入选标准。EDSS 和 T25FW 的早期变化是长期 EDSS 的最佳预测指标;在“单一预测指标”模型中,这两个指标都是显著的预测指标。早期 EDSS 变化是一个稍强的单一预测指标(R(2)0.38,Wald χ(2)42.65,p < 0.001),而早期 T25FW 变化的预测能力稍弱(R(2)0.27,Wald χ(2)12.35,p < 0.001)。在“联合预测指标”模型中,将早期 T25FW 变化添加到早期 EDSS 变化中,可提高预测效果(p = 0.036)。

结论

EDSS 和 T25FW 的早期变化都能以相当的强度预测长期 EDSS。T25FW 的早期变化可提供重要的独立信息,并可改善仅基于 EDSS 早期变化的预测模型。因此,我们支持在未来的进展性 MS 临床试验中使用早期 T25FW 检查。

相似文献

1
Clinical scales in progressive MS: predicting long-term disability.进展性多发性硬化症的临床量表:预测长期残疾。
Mult Scler. 2012 Mar;18(3):345-50. doi: 10.1177/1352458511419880. Epub 2011 Aug 25.
2
Walking speed, rather than Expanded Disability Status Scale, relates to long-term patient-reported impact in progressive MS.在进展性多发性硬化症中,与长期患者报告的影响相关的是步行速度,而不是扩展残疾状况量表。
Mult Scler. 2013 Mar;19(3):326-33. doi: 10.1177/1352458512454346. Epub 2012 Aug 20.
3
The search for responsive clinical endpoints in primary progressive multiple sclerosis.在原发性进行性多发性硬化症中寻找反应性临床终点。
Mult Scler. 2009 Jun;15(6):715-20. doi: 10.1177/1352458509102626. Epub 2009 Apr 21.
4
Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.扩展残疾状态量表(EDSS)和多发性硬化功能综合评分(MSFC)在原发性进行性多发性硬化中的反应性和预测价值。
Neurology. 2008 Mar 25;70(13 Pt 2):1084-91. doi: 10.1212/01.wnl.0000288179.86056.e1. Epub 2008 Jan 9.
5
Detecting clinically-relevant changes in progressive multiple sclerosis.检测进展性多发性硬化症的临床相关变化。
Mult Scler. 2015 Feb;21(2):171-9. doi: 10.1177/1352458514540969. Epub 2014 Jul 10.
6
The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis.EDSS Plus,一种用于继发进展型多发性硬化症残疾进展的改良终点指标。
Mult Scler. 2017 Jan;23(1):94-105. doi: 10.1177/1352458516638941. Epub 2016 Jul 11.
7
The natural history of primary progressive MS in British Columbia, Canada.加拿大不列颠哥伦比亚省原发性进行性多发性硬化症的自然病史。
Neurology. 2005 Dec 27;65(12):1919-23. doi: 10.1212/01.wnl.0000188880.17038.1d.
8
Progression on the Multiple Sclerosis Functional Composite in multiple sclerosis: what is the optimal cut-off for the three components?多发性硬化症功能综合指标的进展:三个组成部分的最佳截断值是多少?
Mult Scler. 2010 Jul;16(7):862-7. doi: 10.1177/1352458510370464. Epub 2010 May 20.
9
The natural history of primary progressive multiple sclerosis.原发性进行性多发性硬化症的自然病史。
Neurology. 2009 Dec 8;73(23):1996-2002. doi: 10.1212/WNL.0b013e3181c5b47f.
10
Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis.多发性硬化症中25英尺定时步行试验和9孔插针试验恶化20%的临床影响。
Mult Scler. 2006 Oct;12(5):594-8. doi: 10.1177/1352458506070768.

引用本文的文献

1
A metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration (MACSiMiSE-BRAIN): study protocol for a multi-center randomized placebo controlled clinical trial.二甲双胍治疗多发性硬化症的附加临床试验,以评估脑髓鞘再生和神经退行性变(MACSiMiSE-BRAIN):一项多中心随机安慰剂对照临床试验的研究方案。
Front Immunol. 2024 Feb 21;15:1362629. doi: 10.3389/fimmu.2024.1362629. eCollection 2024.
2
The correlation between 9-HPT and patient-reported measures of upper limb function in multiple sclerosis: a systematic review and meta-analysis.9-HPT 与多发性硬化症患者上肢功能报告测量指标之间的相关性:系统评价和荟萃分析。
J Neurol. 2023 Sep;270(9):4179-4191. doi: 10.1007/s00415-023-11801-3. Epub 2023 Jun 9.
3
Measuring Treatment Response in Progressive Multiple Sclerosis-Considerations for Adapting to an Era of Multiple Treatment Options.评估进展性多发性硬化症的治疗应答——考虑适应多种治疗选择的时代。
Biomolecules. 2021 Sep 10;11(9):1342. doi: 10.3390/biom11091342.
4
Plasma proteome in multiple sclerosis disease progression.多发性硬化症疾病进展中的血浆蛋白质组。
Ann Clin Transl Neurol. 2019 Sep;6(9):1582-1594. doi: 10.1002/acn3.771. Epub 2019 Jul 31.
5
Comparative utility of disability progression measures in PPMS: Analysis of the PROMiSe data set.进展性多发性硬化症中残疾进展测量指标的比较效用:PROMiSe数据集分析
Neurol Neuroimmunol Neuroinflamm. 2017 May 10;4(4):e358. doi: 10.1212/NXI.0000000000000358. eCollection 2017 Jul.
6
Exploration of machine learning techniques in predicting multiple sclerosis disease course.探索机器学习技术在预测多发性硬化症病程中的应用。
PLoS One. 2017 Apr 5;12(4):e0174866. doi: 10.1371/journal.pone.0174866. eCollection 2017.
7
Validating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review.基于系统文献回顾,在一个大型原发性进展型多发性硬化症队列中验证疾病进展的预测因子。
PLoS One. 2014 Mar 20;9(3):e92761. doi: 10.1371/journal.pone.0092761. eCollection 2014.
8
Clinically meaningful performance benchmarks in MS: timed 25-foot walk and the real world.MS 中的临床有意义的绩效基准:定时 25 英尺行走和现实世界。
Neurology. 2013 Nov 19;81(21):1856-63. doi: 10.1212/01.wnl.0000436065.97642.d2. Epub 2013 Oct 30.
9
Opposite roles of NMDA receptors in relapsing and primary progressive multiple sclerosis.N-甲基-D-天冬氨酸受体在复发缓解型和原发进展型多发性硬化中的相反作用。
PLoS One. 2013 Jun 28;8(6):e67357. doi: 10.1371/journal.pone.0067357. Print 2013.
10
Targeting thalamic tremor cells in deep brain stimulation for multiple sclerosis-induced complex tremor.针对丘脑震颤细胞进行深部脑刺激治疗多发性硬化症引起的复杂性震颤。
Surg Neurol Int. 2013 Mar 22;4:31. doi: 10.4103/2152-7806.109464. Print 2013.